CYTOKINE MARKET ANALYSIS

Cytokine Market, By Type (Tumor Necrosis Factor-TNF, Interleukins-II, Interferons-IFN, Epidermal Growth Factor-EGF, and Others), By Therapeutic Application (Cancer, Asthma, Arthritis, Hematology, and Others), By End User (Hospitals, Research laboratories, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On October 22, 2024, UTHealth School of Dentistry in Texas, U.S. announced a multidisciplinary collaboration to explore a novel micro-cytokine factory platform aimed at treating periodontal disease and oral cancer. This initiative seeks to investigate the potential of micro-cytokine factories in advancing therapeutic options for these conditions.
On September 16, 2024, ScaleReady, a provider of cell and gene-modified cell therapy (CGT) using a G-Rex-centric manufacturing platform, and Bio-Techne, a global biotechnology company, announced the launch of G-Rex optimized ProPak GMP Cytokines. This product is specifically designed for high-efficiency closed-system CGT manufacturing and consists of a weldable bag filled with GMP-grade liquid cytokines, including interleukin-7 (IL-7) and interleukin-15 (IL-15). These cytokines are commonly utilized in the ex vivo production of CAR-T and TCR-T cells.
On January 29, 2024, Synthekine Inc., a company specializing in engineered cytokine therapeutics, announced a global collaboration with Sanofi, a biopharmaceutical firm, to develop and commercialize IL-10 receptor agonists for treating inflammatory diseases. IL-10 is a crucial immune-regulatory cytokine that has garnered significant clinical interest for its potential as an immunosuppressive agent.